Oric Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ORIC Pharmaceuticals reports significant clinical progress for rinzimetostat and enozertinib, alongside successful capital raises, as it focuses on overcoming cancer resistance.
NASDAQ
ORIC Pharmaceuticals details its 2024 financial results and provides updates on its clinical development programs, including ORIC-114 and ORIC-944.
NASDAQ
ORIC Pharmaceuticals' 2023 annual report details clinical advancements and financial standing, emphasizing its focus on overcoming cancer resistance.